Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 12404 matches for

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.

Quality in Organ Donation (QUOD) logo
  • QUOD provides access to biospecimens from healthy organ donors and compromised patients with liver disease  
  • Adding data from several thousands of individual specimens significantly expands Evotec's existing patient database and will allow a unique understanding of disease mechanisms across indications

 

Categories

Similar stories

Three hospital trusts participating in an Oxford-led study evaluating AI software for diagnosing prostate cancer in clinical settings

Oxford University Hospitals (OUH) NHS Foundation Trust, North Bristol NHS Trust, and University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are evaluating a new Artificial Intelligence (AI) diagnostic system that could help improve prostate cancer diagnosis.

Professor Tipu Aziz receives inaugural lifetime achievement award

ARTICULATE PRO study releases new videos about the role of AI in prostate cancer diagnosis